July 28, 2017 12:02 AM ET


Company Overview of Ocata Therapeutics, Inc.

Company Overview

Ocata Therapeutics, Inc., a clinical stage biotechnology company, develops and commercializes regenerative ophthalmology therapeutics in the United States. The company is conducting various clinical trials for treating Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration, as well as pre-clinical trials for the treatment of other ocular disorders; and has pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory, and wound healing-related disorders. Its intellectual property portfolio includes pluripotent stem cell platforms, such as human embryonic stem cell and induced pluripotent stem...

33 Locke Drive

Marlborough, MA 01752

United States

37 Employees





Key Executives for Ocata Therapeutics, Inc.

Chief Executive Officer, President and Director
Treasurer and Director
Secretary and Director
Director of Business Development
Vice President of Manufacturing
Compensation as of Fiscal Year 2017.

Ocata Therapeutics, Inc. Key Developments

Ocata Therapeutics, Inc.(NasdaqGM:OCAT) dropped from CRSP US Total Market Index

Ocata Therapeutics, Inc.(NasdaqGM:OCAT) dropped from CRSP US Total Market Index

Ocata Therapeutics, Inc.(NasdaqGM:OCAT) dropped from Russell Global Index

Ocata Therapeutics, Inc.(NasdaqGM:OCAT) dropped from Russell Global Index

Ocata Therapeutics, Inc. Announces Management Changes

Ocata Therapeutics, Inc. on November 10, 2015, the Company entered into an Agreement and Plan of Merger with Astellas Pharma Inc. (Astellas) and Laurel Acquisition Inc., an indirect wholly-owned subsidiary of Astellas (Merger Sub). On February 10, 2016 pursuant to the terms of the Merger Agreement and in accordance with Section 251(h) of the Delaware General Corporation Law (the DGCL), Merger Sub merged with and into the Company, with the Company being the surviving corporation. Effective at the Effective Time, (i) each of Paul K. Wotton, Ph.D., Michael Heffernan, Alan C. Shapiro, Ph.D., Robert Langer, Sc.D., Zohar Loshitzer, Brian Levy, OD, MSc, and Gregory D. Perry resigned from his respective position as a member of the Company's Board of Directors, and any committee thereof, and (ii) each of Paul K. Wotton, Ph.D., Edward Myles, Robert P. Lanza, M.D., Eddy Anglade, and H. LeRoux Jooste ceased to be executive officers of the Company. At the Effective Time, Masao Yoshida became the President and Chief Executive Officer of the Company, Stephen Knowles became the Treasurer of the Company and Linda Friedman became the Secretary of the Company, and each of them became a member of the Company's Board of Directors.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ocata Therapeutics, Inc., please visit www.ocata.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.